batirtze-areitio Batirtze Areitio Batirtze has over 5 years of experience in the biopharma and biotech industries. She joined ApexOnco in 2025 after working as an analyst at OncologyPipeline. She is a graduate of the University of Navarra, where she earned a degree in biochemistry. ASCO 2024 – USP1 lives on, for now 2 June 2024 ASCO 2024 – Pfizer’s KAT6 inhibitor purrs 2 June 2024 ASCO 2024 – two more Echelon-3 surprises 2 June 2024 ASCO 2024 – AbbVie sees SEZ6 improvement 1 June 2024 Ikena rolls over on Hippo 29 May 2024 Setanaxib looks like small beer for Calliditas’s Japanese suitor 28 May 2024 No dato-dxd surprise in squamous lung cancer 28 May 2024 ASCO 2024 preview – first look at Kelun’s registrational TROP2 dataset 23 May 2024 Load More